News & Events about Karyopharm Therapeutics Inc.
Piper Sandler initiated coverage on shares of Karyopharm Therapeutics (NASDAQ:KPTI Get Rating) in a report released on Thursday morning, MarketBeat reports. The firm issued an overweight rating and a $8.00 target price on the stock. A number of other research analysts have also recently weighed in ...
Karyopharm Announces Investor and Analyst Event at ASH 2022 on Selinexor Data in Patients with Treatment-Nave Myelofibrosis Karyopharm Announces Investor and Analyst Event at ASH 2022 on Selinexor Data in Patients with Treatment-Nave Myelofibrosis PR Newswire NEWTON, Mass., Dec. 5, 2022 Key Opinion...
Karyopharm Announces $165 Million Private Placement Karyopharm Announces $165 Million Private Placement PR Newswire NEWTON, Mass., Dec. 5, 2022 NEWTON, Mass., Dec. 5, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer...
Ticker Report
2 months ago
Shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI Get Rating) have been assigned an average recommendation of Moderate Buy from the nine brokerages that are presently covering the firm, MarketBeat.com reports. Four investment analysts have rated the stock with a hold rating ...
CNW Group - News Releases
6 months ago
Karyopharm and Menarini Group Receive Full Marketing Authorisation from the European Commission for NEXPOVIO (selinexor) for the Treatment of Patients with Multiple Myeloma After at Least One Prior Therapy Karyopharm and Menarini Group Receive Full Marketing Authorisation from the European...